Updates

Announcements

Written response received from the FDA

Sep 15, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that, further to the Company’s notification of 7 July 2022, its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. The FDA response was detailed and included significant…
Exercise of Options | L1 Capital

Sep 7, 2022

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 3,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £150,000. New Ordinary Shares and Admission The New Ordinary Shares…
FDA response for Type C Meeting – update

Aug 31, 2022

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announced on 7 July 2022 that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had advised that it had received Type C Meeting confirmation from the Food and Drug Administration (“FDA”). It was announced at that time that : the statement of…
Exercise of Options

Aug 31, 2022

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 2,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £100,000. New Ordinary Shares and Admission The New Ordinary Shares…
Exercise of Options

Aug 24, 2022

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 1,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £50,000. New Ordinary Shares and Admission The New Ordinary Shares…
Lanstead Capital TR1

Aug 18, 2022

TR-1: Standard form for notification of major holdings To download click here
Total Voting Rights

Aug 16, 2022

ImmuPharma plc (“ImmuPharma” or “the Company”), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM. Consequently, the Company’s issued share capital…
Result of Broker Option / PDMR Dealings

Aug 11, 2022

ImmuPharma plc (“ImmuPharma” or “the Company”), announces that it has raised £0.95 million (before expenses) pursuant to a Broker Option following the announcement made on 3 August 2022. Under the terms of a placing agreement entered into by the Company with Stanford Capital Partners Limited (“SCP”) and SPARK Advisory Partners Limited on 3 August, the…
INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022

Aug 4, 2022

ImmuPharma is pleased to announce that Tim McCarthy, CEO and Tim Franklin, COO, will provide a live investor presentation via the Investor Meet Company platform today, 4 August 2022 at 12:00pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until…
Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m

Aug 3, 2022

Related Party Transactions ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a subscription and a placing to raise c£1.1 million (the “Subscription” and “Placing”) through the issue of 21,818,182 new ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 5 pence…
Initiation of research

Jul 7, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes that its joint broker, Stanford Capital Partners (“SCP”) has today initiated research coverage on the Company. The full text of the report can be accessed via SCP’s website: www.stanfordcp.co.uk/research/ and via Research Tree. Investors are required to self-certify and register in order to access…
2022 Result of ANNUAL GENERAL MEETING – all resolutions passed

Jun 28, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. ImmuPharma’s Chairman & CEO, Tim McCarthy said: “We are delighted to have had such overwhelming support from right across…
Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients

Jun 27, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that, having met all the Food and Drug Administration’s (“FDA”) requirements, Avion Pharmaceuticals (“Avion”), its US partner, has confirmed that it has sought final regulatory guidance from the FDA, as it actively prepares for the start of the international Phase 3…
Lanstead Capital Investors LP share holding update

Jun 21, 2022

To download click here
FDA confirms response date for Type C Meeting as 29th August 2022

Jun 11, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has advised that it has now received Type C Meeting confirmation from the Food and Drug Administration (“FDA”). The statement of purpose, objectives, and proposed agenda of the Type C meeting…
Notice of AGM & Annual Report & Accounts

Jun 1, 2022

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2021 will be posted to shareholders on 6 June 2022. These documents will be available shortly, in electronic…
FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021

May 25, 2022

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the “Period”). Key Highlights (including post Period review) Loss for the Period of £8.2m (£6.9m at 31 December 2020) Research and development expenses of £3.7m (31 December 2020: £2.4m)…
UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION

May 4, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that final preparations are now underway to progress Lupuzor™ into its new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Further to the recent positive results from the Lupuzor™/P140 Pharmacokinetic (“PK”) study announced on 13 April 2022, we are…
UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.

Apr 13, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide positive data from the Lupuzor™/P140 pharmacokinetic (“PK”) study, required by the US Food & Drug Administration (”FDA”), as part of the new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Key highlights Data successfully demonstrates the PK study has…
LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently

Feb 7, 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide an update on the Lupuzor™ pharmacokinetic (“PK”) study, as part of the new optimised international Phase 3 trial of Lupuzor™ in Lupus patients. Key highlights Medical and Health Products Regulatory Agency (“MHRA”) approves commencement of the PK study Volunteers have been…
TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022)

Jan 10, 2022

TR-1: Standard form for notification of major holdings To view notification click here

2026 (11)

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Written response received from the FDA

Exercise of Options | L1 Capital

FDA response for Type C Meeting – update

Exercise of Options

Exercise of Options

Lanstead Capital TR1

Total Voting Rights

Result of Broker Option / PDMR Dealings

INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022

Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m

Initiation of research

2022 Result of ANNUAL GENERAL MEETING – all resolutions passed

Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients

Lanstead Capital Investors LP share holding update

FDA confirms response date for Type C Meeting as 29th August 2022

Notice of AGM & Annual Report & Accounts

FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021

UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION

UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.

LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently

TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022)